Minimal intensity diode laser (810 nanometer) photocoagulation (MIP) for diffuse diabetic macular edema (DDME)

R J Olk1, L Akduman

  • 1The Retina Center of St. Louis County, 11710 Old Ballas Rd., Suite 102, St. Louis, MO 63141, USA.

Seminars in Ophthalmology
|October 19, 2004
PubMed
Abstract

Insights

Minimal intensity diode laser (810nm) photocoagulation effectively treats diffuse diabetic macular edema (DDME), reducing or eliminating it in 74% of cases. This method offers improved visual field preservation and reduced scarring compared to older laser treatments.

Area of Science:

  • Ophthalmology
  • Diabetic Retinopathy Treatment
  • Laser Photocoagulation

Background:

  • Diabetic macular edema (DDME) is a leading cause of vision loss in diabetic patients.
  • Current treatments for DDME have limitations, including potential visual field defects and scarring.

Observation:

  • This study evaluated minimal intensity diode laser (810nm) photocoagulation (MIP) for DDME.
  • Patients received MIP or modified grid photocoagulation, with follow-up every 3-4 months.
  • Visual acuity, visual fields, macular edema reduction, and treatment number were assessed.

Findings:

  • MIP achieved reduction/elimination of DDME in approximately 74% of eyes within 24 months.
  • Eighty-eight percent of patients maintained stable visual acuity.
  • Factors like cystoid edema, poor initial acuity, macular ischemia, or hypertension did not negatively impact outcomes.
  • Patients without systemic vascular disease showed better visual stabilization or improvement.
  • MIP resulted in significantly reduced atrophic scarring and fewer pericentral visual field complaints compared to shorter wavelength lasers.

Implications:

  • Minimal intensity diode laser (810nm) photocoagulation is an effective treatment for DDME.
  • This technique offers advantages in preserving visual field function and minimizing retinal scarring.
  • While resolution may be slightly prolonged, MIP presents a safer alternative for managing DDME.